Incyte Presents Phase 1/2 Multidose Data for VGA039 (Latarcibart) at ISTH 2026, Showing Substantial Bleed Reductions in Patients with all Von Willebrand Disease Types

Insmed (INCY) reported Phase 1/2 multidose data for VGA039 (latarcibart) showing substantial reductions in bleeding events across all Von Willebrand disease types. While specific magnitude/percent reductions aren’t provided in the headline text, the results are positioned as clinically meaningful efficacy signals that could support continued development.

Analysis

Insmed (INCY) reported Phase 1/2 multidose data for VGA039 (latarcibart) showing substantial reductions in bleeding events across all Von Willebrand disease types. While specific magnitude/percent reductions aren’t provided in the headline text, the results are positioned as clinically meaningful efficacy signals that could support continued development.